Published in Neurosci Lett on June 16, 2000
Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci (2010) 3.81
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest (2011) 3.53
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J (2010) 1.90
Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2007) 1.63
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna) (2006) 1.33
Role of oxidative stress in Parkinson's disease. Exp Neurobiol (2013) 1.23
Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci (2009) 1.21
Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) (2005) 1.20
Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One (2013) 1.11
Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A (2013) 1.07
The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein. PLoS One (2011) 1.06
Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem (2009) 1.06
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest (2012) 1.05
α-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci (2011) 1.04
Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem (2010) 1.04
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry (2015) 1.04
Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci (2010) 1.01
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
The role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelism. Int J Mol Sci (2012) 0.97
Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants. PLoS One (2010) 0.96
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet (2014) 0.95
Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem (2009) 0.95
Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev (2009) 0.94
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies. PLoS One (2012) 0.93
The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS One (2013) 0.92
Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics (2013) 0.92
An update on the cerebellar subtype of multiple system atrophy. Cerebellum Ataxias (2014) 0.91
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat (2014) 0.90
Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet (2014) 0.90
Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS One (2013) 0.89
Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging (2014) 0.88
Glial cell inclusions and the pathogenesis of neurodegenerative diseases. Neuron Glia Biol (2004) 0.88
Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. Biomed Res Int (2014) 0.88
α-Synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev Neurosci (2010) 0.88
α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One (2012) 0.87
Regulation of Weibel-Palade body exocytosis by alpha-synuclein in endothelial cells. J Biol Chem (2010) 0.87
Role of Ser129 phosphorylation of α-synuclein in melanoma cells. J Cell Sci (2012) 0.87
Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci (2014) 0.86
Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener (2012) 0.86
Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell Models. Biomolecules (2015) 0.86
A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci (2016) 0.86
GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein. Neurosci Lett (2009) 0.85
Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci (2014) 0.85
α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease. PLoS One (2011) 0.84
Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's Disease. Int J Mol Sci (2016) 0.84
Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation. Exp Neurobiol (2014) 0.84
The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules (2015) 0.84
Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther (2009) 0.83
Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front Neurol (2013) 0.83
α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int J Alzheimers Dis (2012) 0.83
Variant in the 3' region of SNCA associated with Parkinson's disease and serum α-synuclein levels. J Neurol (2011) 0.82
Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides (2014) 0.81
α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease. Int J Mol Sci (2010) 0.81
Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim Biophys Acta (2014) 0.81
Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role. Biomolecules (2015) 0.81
Copper and copper proteins in Parkinson's disease. Oxid Med Cell Longev (2014) 0.80
Cerebrospinal fluid biomarkers for dementia with lewy bodies. Int J Alzheimers Dis (2010) 0.79
Cell Biology and Pathophysiology of α-Synuclein. Cold Spring Harb Perspect Med (2017) 0.79
Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? Alzheimers Res Ther (2012) 0.78
Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One (2012) 0.78
Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions. ACS Chem Neurosci (2015) 0.78
Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol (2010) 0.78
Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway. Neural Regen Res (2013) 0.78
Direct Observation of α-Synuclein Amyloid Aggregates in Endocytic Vesicles of Neuroblastoma Cells. PLoS One (2016) 0.78
Is Parkinson's disease truly a prion-like disorder? An appraisal of current evidence. Neurol Res Int (2015) 0.77
Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One (2015) 0.77
Impairment of PDGF-induced chemotaxis by extracellular α-synuclein through selective inhibition of Rac1 activation. Sci Rep (2016) 0.77
Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant. PLoS One (2016) 0.77
The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity. Proc Natl Acad Sci U S A (2016) 0.76
Bridging molecular genetics and biomarkers in lewy body and related disorders. Int J Alzheimers Dis (2011) 0.76
Disease-modifying therapeutic directions for Lewy-Body dementias. Front Neurosci (2015) 0.76
Disease-Toxicant Interactions in Parkinson's Disease Neuropathology. Neurochem Res (2016) 0.76
Exogenous Alpha-Synuclein Alters Pre- and Post-Synaptic Activity by Fragmenting Lipid Rafts. EBioMedicine (2016) 0.75
Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach. Front Neurosci (2017) 0.75
Extracellular α-synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β-arrestin signal intact. Sci Rep (2017) 0.75
More than a Rumor Spreads in Parkinson's Disease. Front Hum Neurosci (2016) 0.75
Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxicity induced by alpha-synuclein. Proteomics (2010) 0.75
Serological Analysis of Alpha-synuclein and NF-κB in Parkinson's Disease Patients. J Clin Diagn Res (2015) 0.75
Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. BMC Neurol (2016) 0.75
Familial Parkinson's Disease Mutant E46K α-Synuclein Localizes to Membranous Structures, Forms Aggregates, and Induces Toxicity in Yeast Models. ISRN Neurol (2011) 0.75
Modulating the Amyloidogenesis of α-Synuclein. Curr Neuropharmacol (2016) 0.75
The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion. Aging (Albany NY) (2017) 0.75
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science (1992) 3.93
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med (1996) 2.71
Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology (2005) 2.69
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology (2007) 2.51
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
DISTRIBUTION OF RADIOACTIVE SULFUR IN THE RAT. Science (1945) 2.23
Environmental risk factors and clinical phenotype in familial and sporadic primary blepharospasm. Neurology (2011) 2.10
Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc Natl Acad Sci U S A (1988) 2.04
Presenilin-1 mutations in Alzheimer's disease. Nature (2000) 1.97
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology (2010) 1.93
Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science (1997) 1.70
Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A (1993) 1.68
Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem (1998) 1.68
Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes. J Biol Chem (1986) 1.62
Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. J Alzheimers Dis (2000) 1.61
Evaluation of quinacrine treatment for prion diseases. J Virol (2003) 1.59
Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology (2010) 1.59
Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol (1999) 1.49
Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. Ital J Neurol Sci (1997) 1.46
Bilateral analgesia and unilateral paresis after lumbar epidural blockade. Anesth Analg (1992) 1.38
DRD3 Ser9Gly variant is not associated with essential tremor in a series of Italian patients. Eur J Neurol (2008) 1.37
Glutaraldehyde-tanned mandril-grown grafts as venous substitutes. J Thorac Cardiovasc Surg (1991) 1.37
Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol (2000) 1.32
Comparison of MicroScan WalkAway system and Vitek system for identification of gram-negative bacteria. J Clin Microbiol (1995) 1.31
REM sleep behaviour disorder in Parkinson's disease: a questionnaire-based study. Neurol Sci (2005) 1.30
Abnormalities of sensorimotor integration in focal dystonia: a transcranial magnetic stimulation study. Brain (2001) 1.23
Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem Biophys Res Commun (1993) 1.23
Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology (2004) 1.23
Identification of prion protein gene polymorphisms in goats from Italian scrapie outbreaks. J Gen Virol (2006) 1.22
Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci U S A (1998) 1.22
Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am J Pathol (1992) 1.20
Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease. Parkinsonism Relat Disord (2008) 1.16
Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens (1995) 1.16
Alternative, non-secretase processing of Alzheimer's beta-amyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem (1999) 1.15
The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov Disord (2000) 1.14
Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun (2000) 1.14
Tau gene mutation in familial progressive subcortical gliosis. Nat Med (1999) 1.13
A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry (2006) 1.13
Tonic vibration reflex in Holmes-Adie syndrome: an electrophysiological study. J Neurol Neurosurg Psychiatry (1979) 1.12
Surface recording of the spinal ventral root discharge in man. An experimental study. Brain (1983) 1.11
Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett (1997) 1.11
Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. J Neurosci (1991) 1.10
Analysis of the prion protein gene in thalamic dementia. Neurology (1992) 1.09
Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group. J Neurol Neurosurg Psychiatry (1998) 1.09
Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol (2000) 1.09
Crystal structure and refolding properties of the mutant F99S/M153T/V163A of the green fluorescent protein. Proteins (2000) 1.08
Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J Biol Chem (1994) 1.07
Selective presence of ubiquitin in intracellular inclusions. Am J Pathol (1989) 1.07
Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neurosci Lett (1995) 1.06
KDC1, a novel carrot root hair K+ channel. Cloning, characterization, and expression in mammalian cells. J Biol Chem (2000) 1.06
Motor recovery following stroke: a transcranial magnetic stimulation study. Clin Neurophysiol (2000) 1.06
Gene variants with suicidal risk in a sample of subjects with chronic migraine and affective temperamental dysregulation. Eur Rev Med Pharmacol Sci (2012) 1.04
Time-course of c-Jun N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun and caspase-3 activation. Neuroscience (2007) 1.02
Alpha-naphthyl acetate esterase activity in human lymphocytes: distribution in lymphocyte subpopulations and in mitogen-activated cells. Scand J Immunol (1979) 1.02
A three-dimensional study of the normal human placental villous core. I. The Hofbauer cells. Cell Tissue Res (1980) 1.01
"Bolus" methylprednisolone versus ACTH in the treatment of multiple sclerosis. Ital J Neurol Sci (1983) 1.01
Selective facilitation of responses to cortical stimulation of proximal and distal arm muscles by precision tasks in man. J Physiol (1996) 1.01
Familial progressive subcortical gliosis: presence of prions and linkage to chromosome 17. Neurology (1995) 1.00
Electroneurographic correlates of the monosynaptic reflex: experimental studies and normative data. J Neurol Neurosurg Psychiatry (1985) 0.99
Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem J (1999) 0.98
Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J (2000) 0.97
Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun (1998) 0.96
Long-term assessment of the risk of spread in primary late-onset focal dystonia. J Neurol Neurosurg Psychiatry (2007) 0.96
Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line. J Neurosci Res (1998) 0.96
The relationship between cerebral vascular disease and parkinsonism: The VADO study. Parkinsonism Relat Disord (2012) 0.96
A novel presenilin 1 L166H mutation in a pseudo-sporadic case of early-onset Alzheimer's disease. Neurol Sci (2005) 0.95
The peripheral dopaminergic system: morphological analysis, functional and clinical applications. Ital J Anat Embryol (2002) 0.95
Differentiation and proliferation patterns in human trophoblast revealed by c-erbB-2 oncogene product and EGF-R. J Histochem Cytochem (1993) 0.95
Neurotransmitters, neuroreceptors and aging. Mech Ageing Dev (1991) 0.95
Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J Neurochem (1989) 0.94
Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychiatry (1999) 0.94
The rationale for motor learning in Parkinson's disease. Eur J Phys Rehabil Med (2009) 0.94
Role of the hippocampus in the sex-dependent regulation of eating behavior: studies with kainic acid. Physiol Behav (1986) 0.94
Letter: T and B lymphocytes in normal cerebrospinal fluid. N Engl J Med (1976) 0.93
Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol (1998) 0.93
Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet (2000) 0.92
New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism. Neurology (2001) 0.92
Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol (1984) 0.91
Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J Neurochem (1998) 0.91
Zoster sine herpete causing encephalomyelitis. Ital J Neurol Sci (1987) 0.91
Huntington's disease: survival of large striatal neurons in the rigid variant. Ann Neurol (1984) 0.91
Changes of intracortical inhibition during motor imagery in human subjects. Neurosci Lett (1999) 0.91
Primary hemifacial spasm and arterial hypertension: a multicenter case-control study. Neurology (2000) 0.90
Dystrophic neurites infiltrate extracellular neurofibrillary tangles in Alzheimer disease. Brain Res (1991) 0.89